Jefferies upgraded Aurinia Pharmaceuticals (AUPH) to Buy from Hold with a price target of $21, up from $10. The company’s commercial performance with Lupkynis has driven a strong balance sheet and positive cash flow, the analyst tells investors in a research note. The firm also sees Aurinia’s BAFF/APRIL inhibitor aritinercept as “under-the-radar” with a “derisked” mechanism of action. The drug should get more attention as Aurinia announced a development path in early 2026, contends Jefferies.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals Reports Strong Q3 2025 Earnings
- Aurinia Pharma’s Earnings Call Highlights Growth and Challenges
- Aurinia downgraded to Sector Perform from Outperform at RBC Capital
- Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals
- Aurinia Pharmaceuticals Boosts 2025 Sales Guidance Amid Strong Q3 Performance